AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39388183 — intervention group
Group type: EXPERIMENTAL
Intervention: EMAF plus PF plus PPC (most intensive strategy)
Number of subjects: 8978
Study 39388183 — intervention group
Group type: COMPARATOR
Intervention: EMAF (least intensive strategy)
Number of subjects: 8978
Study 39388196 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral Laser Microsurgery (TLM)
Number of subjects: 508
Study 39388196 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery (TORS)
Number of subjects: 508
Study 39388228 — intervention group
Group type: EXPERIMENTAL
Intervention: P3 DHI (couples-based, digital HIV serostatus-neutral intervention) for 6 months
Number of subjects: 74
Study 39388228 — intervention group
Group type: COMPARATOR
Intervention: Delayed control condition (access to P3 DHI for last 3 months)
Number of subjects: 74
Study 39388231 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal health services intervention (technology-enabled, telehealth-delivered, 4-level intervention)
Number of subjects: 190
Study 39388231 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal health services intervention
Number of subjects: 190
Study 39388231 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 190
Study 39388670 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That HEAL Intervention
Number of subjects: 0
Study 39388670 — intervention group
Group type: COMPARATOR
Intervention: Wait-List Control
Number of subjects: 0
Study 39388688 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (mobile health app)
Number of subjects: 98
Study 39388851 — intervention group
Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO intervention
Number of subjects: 109
Study 39388851 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 109
Study 39388898 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvaliase treatment
Number of subjects: 109
Study 39389055 — intervention group
Group type: EXPERIMENTAL
Intervention: Zorifertinib
Number of subjects: 439
Study 39389055 — intervention group
Group type: COMPARATOR
Intervention: Control (first-generation EGFR-TKI: gefitinib or erlotinib)
Number of subjects: 439
Study 39389055 — intervention group
Group type: COMPARATOR
Intervention: Control (first-generation EGFR-TKI)
Number of subjects: 439
Study 39389071 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam-avibactam
Number of subjects: 422
Study 39389071 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 422
Study 39389071 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam-avibactam (for complicated intra-abdominal infection)
Number of subjects: 422
Study 39389071 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (for complicated intra-abdominal infection)
Number of subjects: 422
Study 39389071 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam-avibactam (for HAP-VAP)
Number of subjects: 422
Study 39389071 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (for HAP-VAP)
Number of subjects: 422
Study 39389076 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-MERS-S vaccine (10^8 PFU) administered intramuscularly in three doses at 28-day intervals
Number of subjects: 140
Study 39389076 — intervention group
Group type: EXPERIMENTAL
Intervention: Second vaccination with MVA-MERS-S (10^8 PFU)
Number of subjects: 140
Study 39389081 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-2218 200 mg subcutaneously every 4 weeks (cohort 1)
Number of subjects: 84
Study 39389081 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 2)
Number of subjects: 84
Study 39389081 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 3)
Number of subjects: 84
Study 39389081 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 4)
Number of subjects: 84
Study 39389081 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 5)
Number of subjects: 84
Study 39389081 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 6)
Number of subjects: 84
Study 39389081 — intervention group
Group type: EXPERIMENTAL
Intervention: VIR-2218 200 mg subcutaneously every 4 weeks
Number of subjects: 84
Study 39389081 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 84
Study 39389294 — intervention group
Group type: EXPERIMENTAL
Intervention: Tour of the NIH Clinical Center with unique events at ten specific locations; memory tested after 1 hour and fifteen months.
Number of subjects: 1
Study 39389294 — intervention group
Group type: COMPARATOR
Intervention: Subsequent recognition memory tests using novel picture stimuli in a standard laboratory-style computer task.
Number of subjects: 1
Study 39389429 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 379
Study 39389429 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 379
Study 39389429 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 379
Study 39389587 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral Quadratus Lumborum Block (QLB)
Number of subjects: 101
Study 39389587 — intervention group
Group type: COMPARATOR
Intervention: Pericapsular Nerve Group Block (PENG) + Lateral Femoral Cutaneous Nerve Block (LFC)
Number of subjects: 101
Study 39389596 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical intention (PI)
Number of subjects: 40
Study 39389598 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic LED lighting scenario (higher daytime and lower evening-time melanopic daylight equivalent illuminance)
Number of subjects: 0
Study 39389598 — intervention group
Group type: COMPARATOR
Intervention: Standard lighting scenario (dynamic colour temperature and fixed light intensity)
Number of subjects: 0
Study 39389598 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic LED lighting scenario
Number of subjects: 0
Study 39389599 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-derived organoids (PDOs) generated from HNSCC samples
Number of subjects: 0
Study 39389599 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood and biological samples (plasma and saliva) collected during treatment
Number of subjects: 0
Study 39389599 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-culture experiments with PDOs
Number of subjects: 0
Study 39389623 — intervention group
Group type: EXPERIMENTAL
Intervention: Very preterm born children (<28 and 28-31 weeks gestational age)
Number of subjects: 442
Study 39389623 — intervention group
Group type: COMPARATOR
Intervention: Fullterm born siblings
Number of subjects: 442
Study 39389623 — intervention group
Group type: COMPARATOR
Intervention: Healthy children from the same time period (secondary analysis)
Number of subjects: 442
Study 39390132 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bevacizumab-800CW
Number of subjects: 18
Study 39390132 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg bevacizumab-800CW
Number of subjects: 18
Study 39390228 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly restored implant (PICF)
Number of subjects: 10
Study 39390228 — intervention group
Group type: COMPARATOR
Intervention: Contralateral tooth (GCF)
Number of subjects: 10
Study 39390276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum KABP042 + Pediococcus pentosaceus KABP041 (BL + PP)
Number of subjects: 112
Study 39390276 — intervention group
Group type: COMPARATOR
Intervention: Limosilactobacillus reuteri DSM17938 (LR)
Number of subjects: 112
Study 39390362 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise program (16-week, 2-3 sessions/week, 60 min/session)
Number of subjects: 56
Study 39390362 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (maintained usual activity, received monthly health education talk)
Number of subjects: 56
Study 39390398 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA booster vaccine
Number of subjects: 0
Study 39390466 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Determined Disease Steps (PDDS) scale
Number of subjects: 374
Study 39390466 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed 25-foot walk (T25FW)
Number of subjects: 374
Study 39390466 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-minute walk (6 MW)
Number of subjects: 374
Study 39390466 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Walking Scale-12 (MSWS-12)
Number of subjects: 374
Study 39390466 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Fatigue Impact Scale (MFIS)
Number of subjects: 374
Study 39390466 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Impact Scale-29 (MSIS-29)
Number of subjects: 374
Study 39390476 — intervention group
Group type: EXPERIMENTAL
Intervention: Student citizens' assembly
Number of subjects: 30
Study 39390508 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary DPP-4
Number of subjects: 45
Study 39390508 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum DPP-4
Number of subjects: 45
Study 39390583 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPD dosing calculator for AUC-based dosing with extra sampling for therapeutic drug monitoring
Number of subjects: 0
Study 39390583 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care dosing and monitoring according to institutional guidelines
Number of subjects: 0
Study 39390601 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-FC (Chicago Parent Program adapted for foster and kinship caregivers)
Number of subjects: 300
Study 39390601 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study 39390601 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-FC
Number of subjects: 300
Study 39390616 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1707 (2, 6, 20, 40, and 60 mg/kg)
Number of subjects: 92
Study 39390616 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1707 (20 mg/kg)
Number of subjects: 92
Study 39390616 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1707 (2-60 mg/kg)
Number of subjects: 92
Study 39390616 — intervention group
Group type: COMPARATOR
Intervention: SHR-1707
Number of subjects: 92
Study 39390669 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with adults with disabilities and complex health conditions
Number of subjects: 18
Study 39390760 — intervention group
Group type: EXPERIMENTAL
Intervention: White button mushroom (WBM) treatment
Number of subjects: 0
Study 39390760 — intervention group
Group type: EXPERIMENTAL
Intervention: White button mushroom (WBM) tablets for 3 months
Number of subjects: 0
Study 39390760 — intervention group
Group type: EXPERIMENTAL
Intervention: WBM combined with PD-1 blockade in murine models
Number of subjects: 0
Study 39390990 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher white blood cell (WBC) counts
Number of subjects: 0
Study 39390990 — intervention group
Group type: COMPARATOR
Intervention: Lower white blood cell (WBC) counts
Number of subjects: 0
Study 39391083 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based family psychoeducation (MBFPE)
Number of subjects: 65
Study 39391083 — intervention group
Group type: COMPARATOR
Intervention: Ordinary family psychoeducation (FPE)
Number of subjects: 65
Study 39391228 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS followed by ET
Number of subjects: 0
Study 39391228 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS followed by ET
Number of subjects: 0
Study 39391324 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM-guided blood product transfusion
Number of subjects: 40
Study 39391324 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) based on conventional coagulation test (CCT)
Number of subjects: 40
Study 39391753 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLE Exoskeleton
Number of subjects: 10
Study 39391887 — intervention group
Group type: EXPERIMENTAL
Intervention: Alberta Family Integrated Care (FICare)
Number of subjects: 455
Study 39391887 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 455
Study 39391887 — intervention group
Group type: EXPERIMENTAL
Intervention: Alberta FICare
Number of subjects: 455
Study 39391887 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal breastfeeding self-efficacy
Number of subjects: 455
Study 39391984 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased oxygen extraction fraction (OEF) within DWI lesions
Number of subjects: 134
Study 39391984 — intervention group
Group type: COMPARATOR
Intervention: No increased oxygen extraction fraction (OEF) within DWI lesions
Number of subjects: 134
Study 39392121 — intervention group
Group type: EXPERIMENTAL
Intervention: ALDH1A1/2 activity in bone marrow (BM)
Number of subjects: 0
Study 39392121 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive oxygen species (ROS) levels
Number of subjects: 0
Study 39392161 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized intervention pathway activated by high-risk scores; nurse-implemented uptitration of diuretic for 4 days
Number of subjects: 59
Study 39392168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase
Number of subjects: 0
Study 39392168 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 0
Study 39392467 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction exercise (BFRE) at 40% total arterial occlusion pressure, using 30-40% of 1-repetition maximum loads, conducted twice weekly for two weeks
Number of subjects: 6
Study 39392470 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with SCI
Number of subjects: 25
Study 39392616 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based mobile texting platform delivering 4 treatment modules (education and behavioral modification, cognitive behavioral therapy, pelvic floor physical therapy, guided mindfulness practices) and an automated weekly message over 6 weeks
Number of subjects: 52
Study 39392616 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based mobile texting platform
Number of subjects: 52
Study 39392675 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful and Self-Compassionate Care (MASC) program, a 6-week online intervention
Number of subjects: 80
Study 39392675 — intervention group
Group type: COMPARATOR
Intervention: Health Education Program
Number of subjects: 80
Study 39392741 — intervention group
Group type: EXPERIMENTAL
Intervention: Any intervention letter
Number of subjects: 299881
Study 39392741 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated letter sent 10 days after the initial letter
Number of subjects: 299881
Study 39392741 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter emphasizing potential cardiovascular benefits of vaccination
Number of subjects: 299881
Study 39392741 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no letter)
Number of subjects: 299881
Study 39392862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessment using KABC-II
Number of subjects: 1366
Study 39392862 — intervention group
Group type: EXPERIMENTAL
Intervention: School achievement test score
Number of subjects: 1366
Study 39392862 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function assessment
Number of subjects: 1366
Study 39392862 — intervention group
Group type: COMPARATOR
Intervention: Growth and physical function outcomes
Number of subjects: 1366
Study 39393026 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Nivolumab
Number of subjects: 0
Study 39393026 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39393045 — intervention group
Group type: EXPERIMENTAL
Intervention: IV natalizumab Q6W dosing
Number of subjects: 486
Study 39393045 — intervention group
Group type: COMPARATOR
Intervention: IV natalizumab Q4W dosing
Number of subjects: 486
Study 39393045 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Q6W vs Q4W dosing
Number of subjects: 486
Study 39393054 — intervention group
Group type: EXPERIMENTAL
Intervention: Apsou mobile serious game for automated detection of NDs
Number of subjects: 229
Study 39393084 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-mg admilparant
Number of subjects: 0
Study 39393084 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-mg admilparant
Number of subjects: 0
Study 39393084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39393172 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF)
Number of subjects: 72
Study 39393177 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-enhanced training models
Number of subjects: 65
Study 39393177 — intervention group
Group type: COMPARATOR
Intervention: Standard 3D LapPass training models
Number of subjects: 65
Study 39393494 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) breakfast
Number of subjects: 30
Study 39393494 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-Protein (NP) breakfast
Number of subjects: 30
Study 39393494 — intervention group
Group type: COMPARATOR
Intervention: Breakfast-skipping (BS) group
Number of subjects: 30
Study 39393498 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating in the absence of hunger (EAH)
Number of subjects: 72
Study 39393498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet food EAH
Number of subjects: 72
Study 39393498 — intervention group
Group type: EXPERIMENTAL
Intervention: Savory food EAH
Number of subjects: 72
Study 39393498 — intervention group
Group type: EXPERIMENTAL
Intervention: High MVPA and low sedentary time
Number of subjects: 72
Study 39393528 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA) with sevoflurane-dexmedetomidine, continuous infusion of lidocaine and ketamine, and magnesium sulfate during induction
Number of subjects: 155
Study 39393528 — intervention group
Group type: COMPARATOR
Intervention: Opioid-sparing anesthesia (OSA) with sevoflurane-sufentanil boluses and continuous infusion of lidocaine
Number of subjects: 155
Study 39393528 — intervention group
Group type: EXPERIMENTAL
Intervention: OFA group
Number of subjects: 155
Study 39393528 — intervention group
Group type: COMPARATOR
Intervention: OSA group
Number of subjects: 155
Study 39393530 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Nipple Sparing Mastectomy (E-NSM)
Number of subjects: 10
Study 39393777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (±bevacizumab)
Number of subjects: 617
Study 39393777 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (±bevacizumab)
Number of subjects: 617
Study 39393844 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow mesenchymal stromal cells (BM-MSCs) - 20 million cells via intradiscal injection
Number of subjects: 114
Study 39393844 — intervention group
Group type: COMPARATOR
Intervention: Sham placebo injection
Number of subjects: 114
Study 39393844 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic BM-MSCs
Number of subjects: 114
Study 39393844 — intervention group
Group type: COMPARATOR
Intervention: Sham placebo
Number of subjects: 114
Study 39393926 — intervention group
Group type: EXPERIMENTAL
Intervention: Allied healthcare
Number of subjects: 1333
Study 39394025 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical vibration
Number of subjects: 105
Study 39394025 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study 39394025 — intervention group
Group type: COMPARATOR
Intervention: ShotBlocker®
Number of subjects: 105
Study 39394112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi)
Number of subjects: 102
Study 39394112 — intervention group
Group type: COMPARATOR
Intervention: Peripheral Oxygen Saturation (SpO2)
Number of subjects: 102
Study 39394126 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with spastic CP (MAL)
Number of subjects: 28
Study 39394126 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with spastic CP (LAL)
Number of subjects: 28
Study 39394126 — intervention group
Group type: COMPARATOR
Intervention: Typically developing children
Number of subjects: 28
Study 39394132 — intervention group
Group type: EXPERIMENTAL
Intervention: ScreenMen web-based app
Number of subjects: 47
Study 39394132 — intervention group
Group type: EXPERIMENTAL
Intervention: QR codes on buntings
Number of subjects: 47
Study 39394132 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcards
Number of subjects: 47
Study 39394132 — intervention group
Group type: EXPERIMENTAL
Intervention: Identify and prepare champions strategy
Number of subjects: 47
Study 39394132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandate change strategy
Number of subjects: 47
Study 39394158 — intervention group
Group type: EXPERIMENTAL
Intervention: CR + BWLT (12 weekly, group-based virtual sessions, followed by 12 weeks of follow-up support)
Number of subjects: 120
Study 39394158 — intervention group
Group type: COMPARATOR
Intervention: CR-only (supervised exercise and risk factor self-management for 12 weeks)
Number of subjects: 120
Study 39394158 — intervention group
Group type: EXPERIMENTAL
Intervention: CR + BWLT
Number of subjects: 120
Study 39394158 — intervention group
Group type: COMPARATOR
Intervention: CR-only
Number of subjects: 120
Study 39394167 — intervention group
Group type: EXPERIMENTAL
Intervention: Health dialogue intervention (systematic screening followed by an individually oriented lifestyle-focused health dialogue)
Number of subjects: 3000
Study 39394167 — intervention group
Group type: COMPARATOR
Intervention: Opportunistic screening (screening for a smaller set of risk factors during an appointment for other reasons)
Number of subjects: 3000
Study 39394167 — intervention group
Group type: EXPERIMENTAL
Intervention: Health dialogue intervention
Number of subjects: 3000
Study 39394167 — intervention group
Group type: EXPERIMENTAL
Intervention: Health dialogue intervention and opportunistic screening
Number of subjects: 3000
Study 39394177 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and temozolomide
Number of subjects: 34
Study 39394177 — intervention group
Group type: EXPERIMENTAL
Intervention: Omics features
Number of subjects: 34
Study 39394177 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway analysis
Number of subjects: 34
Study 39394183 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b
Number of subjects: 109